14 results on '"Kullberg, Bart-Jan"'
Search Results
2. Towards personalized medicine: a scoping review of immunotherapy in sepsis.
- Author
-
Slim, Marleen A., van Mourik, Niels, Bakkerus, Lieke, Fuller, Katherine, Acharya, Lydia, Giannidis, Tatiana, Dionne, Joanna C., Oczkowski, Simon J. W., Netea, Mihai G., Pickkers, Peter, Giamarellos-Bourboulis, Evangelos J., Müller, Marcella C. A., van der Poll, Tom, Wiersinga, W. Joost, Kullberg, Bart-Jan, Nooijer, Aline, Veerdonk, Frank, Oever, Jaap, Hoogerwerf, Jacobien, and Hulscher, Marlies
- Abstract
Despite significant progress in our understanding of the pathophysiology of sepsis and extensive clinical research, there are few proven therapies addressing the underlying immune dysregulation of this life-threatening condition. The aim of this scoping review is to describe the literature evaluating immunotherapy in adult patients with sepsis, emphasizing on methods providing a "personalized immunotherapy" approach, which was defined as the classification of patients into a distinct subgroup or subphenotype, in which a patient's immune profile is used to guide treatment. Subgroups are subsets of sepsis patients, based on any cut-off in a variable. Subphenotypes are subgroups that can be reliably discriminated from other subgroup based on data-driven assessments. Included studies were randomized controlled trials and cohort studies investigating immunomodulatory therapies in adults with sepsis. Studies were identified by searching PubMed, Embase, Cochrane CENTRAL and ClinicalTrials.gov, from the first paper available until January 29th, 2024. The search resulted in 15,853 studies. Title and abstract screening resulted in 1409 studies (9%), assessed for eligibility; 771 studies were included, of which 282 (37%) were observational and 489 (63%) interventional. Treatment groups included were treatments targeting the innate immune response, the complement system, coagulation and endothelial dysfunction, non-pharmalogical treatment, pleiotropic drugs, immunonutrition, concomitant treatments, Traditional Chinese Medicine, immunostimulatory cytokines and growth factors, intravenous immunoglobulins, mesenchymal stem cells and immune-checkpoint inhibitors. A personalized approach was incorporated in 70 studies (9%). Enrichment was applied using cut-offs in temperature, laboratory, biomarker or genetic variables. Trials often showed conflicting results, possibly due to the lack of patient stratification or the potential influence of severity and timing on immunomodulatory therapy results. When a personalized approach was applied, trends of clinical benefit for several interventions emerged, which hold promise for future clinical trials using personalized immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project
- Author
-
Bassetti, Matteo, Giacobbe, Daniele R., Vena, Antonio, Trucchi, Cecilia, Ansaldi, Filippo, Antonelli, Massimo, Adamkova, Vaclava, Alicino, Cristiano, Almyroudi, Maria-Panagiota, Atchade, Enora, Azzini, Anna M., Carannante, Novella, Carnelutti, Alessia, Corcione, Silvia, Cortegiani, Andrea, Dimopoulos, George, Dubler, Simon, García-Garmendia, José L., Girardis, Massimo, Cornely, Oliver A., Ianniruberto, Stefano, Kullberg, Bart Jan, Lagrou, Katrien, Le Bihan, Clement, Luzzati, Roberto, Malbrain, Manu L. N. G., Merelli, Maria, Marques, Ana J., Martin-Loeches, Ignacio, Mesini, Alessio, Paiva, José-Artur, Peghin, Maddalena, Raineri, Santi Maurizio, Rautemaa-Richardson, Riina, Schouten, Jeroen, Brugnaro, Pierluigi, Spapen, Herbert, Tasioudis, Polychronis, Timsit, Jean-François, Tisa, Valentino, Tumbarello, Mario, van den Berg, Charlotte H. S. B., Veber, Benoit, Venditti, Mario, Voiriot, Guillaume, Wauters, Joost, and Montravers, Philippe
- Published
- 2019
- Full Text
- View/download PDF
4. Functional Consequences of Toll-like Receptor 4 Polymorphisms
- Author
-
Ferwerda, Bart, McCall, Matthew B. B., Verheijen, Karlijn, Kullberg, Bart-Jan, van der Ven, André J. A. M., Van der Meer, Jos W. M., and Netea, Mihai G.
- Published
- 2008
- Full Text
- View/download PDF
5. An electronic trigger tool to optimise intravenous to oral antibiotic switch: a controlled, interrupted time series study.
- Author
-
Berrevoets, Marvin A. H., Pot, Johannes (Hans) L. W., Houterman, Anne E., Dofferhoff, Anton (Ton) S. M., Nabuurs-Franssen, Marrigje H., Fleuren, Hanneke W. H. A., Kullberg, Bart-Jan, Schouten, Jeroen A., and Sprong, Tom
- Subjects
ANTIBIOTICS ,PATIENT safety ,ANTI-infective agents - Abstract
Background: Timely switch from intravenous (iv) antibiotics to oral therapy is a key component of antimicrobial stewardship programs in order to improve patient safety, promote early discharge and reduce costs. We have introduced a time-efficient and easily implementable intervention that relies on a computerized trigger tool, which identifies patients who are candidates for an iv to oral antibiotic switch. Methods: The intervention was introduced on all internal medicine wards in a teaching hospital. Patients were automatically identified by an electronic trigger tool when parenteral antibiotics were used for >48 h and clinical or pharmacological data did not preclude switch therapy. A weekly educational session was introduced to alert the physicians on the intervention wards. The intervention wards were compared with control wards, which included all other hospital wards. An interrupted time-series analysis was performed to compare the pre-intervention period with the post-intervention period using '% of i.v. prescriptions >72 h' and 'median duration of iv therapy per prescription' as outcomes. We performed a detailed prospective evaluation on a subset of 244 prescriptions to evaluate the efficacy and appropriateness of the intervention. Results: The number of intravenous prescriptions longer than 72 h was reduced by 19% in the intervention group (n = 1519) (p < 0.01) and the median duration of iv antibiotics was reduced with 0.8 days (p = <0.05). Compared to the control group (n = 4366) the intervention was responsible for an additional decrease of 13% (p < 0.05) in prolonged prescriptions. The detailed prospective evaluation of a subgroup of patients showed that adherence to the electronic reminder was 72%. Conclusions: An electronic trigger tool combined with a weekly educational session was effective in reducing the duration of intravenous antimicrobial therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Monitoring, documenting and reporting the quality of antibiotic use in the Netherlands: a pilot study to establish a national antimicrobial stewardship registry.
- Author
-
Berrevoets, Marvin A. H., ten Oever, Jaap, Sprong, Tom, van Hest, Reinier M., Groothuis, Ingeborg, van Heijl, Inger, Schouten, Jeroen A., Hulscher, Marlies E., Kullberg, Bart-Jan, and Berrevoets, Marvin Ah
- Subjects
ANTIBIOTICS ,ANTI-infective agents ,HOSPITALS ,STAPHYLOCOCCUS aureus ,PILOT projects ,HOSPITAL statistics ,BACTEREMIA ,STAPHYLOCOCCAL diseases ,ACQUISITION of data - Abstract
Background: The Dutch Working Party on Antibiotic Policy is developing a national antimicrobial stewardship registry. This registry will report both the quality of antibiotic use in hospitals in the Netherlands and the stewardship activities employed. It is currently unclear which aspects of the quality of antibiotic use are monitored by antimicrobial stewardship teams (A-teams) and can be used as indicators for the stewardship registry. In this pilot study we aimed to determine which stewardship objectives are eligible for the envisioned registry.Methods: We performed an observational pilot study among five Dutch hospitals. We assessed which of the 14 validated stewardship objectives (11 process of care recommendations and 3 structure of care recommendations) the A-teams monitored and documented in individual patients. They provided, where possible, data to compute quality indicator (QI) performance scores in line with recently developed QIs to measure appropriate antibiotic use in hospitalized adults for the period of January 2015 through December 2015 RESULTS: All hospitals had a local antibiotic guideline describing recommended antimicrobial use. All A-teams monitored the performance of bedside consultations in Staphylococcus aureus bacteremia and the prescription of restricted antimicrobials. Documentation and reporting were the best for the use of restricted antimicrobials: 80% of the A-teams could report data. Lack of time and the absence of an electronic medical record system enabling documentation during the daily work flow were the main barriers hindering documentation and reporting.Conclusions: Five out of 11 stewardship objectives were actively monitored by A-teams. Without extra effort, 4 A-teams could report on the quality of use of restricted antibiotics. Therefore, this aspect of antibiotic use should be the starting point of the national antimicrobial stewardship registry. Our registry is expected to become a powerful tool to evaluate progress and impact of antimicrobial stewardship programs in hospitals. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
7. Clindamycin-rifampin combination therapy for staphylococcal periprosthetic joint infections: a retrospective observational study.
- Author
-
Leijtens, Borg, Elbers, Joris B. W., Sturm, Patrick D., Kullberg, Bart Jan, and Schreurs, Berend W.
- Subjects
CLINDAMYCIN ,RIFAMPIN ,STAPHYLOCOCCAL diseases ,JOINT diseases ,KNEE diseases ,ANTIBIOTICS ,ARTIFICIAL joints ,COMBINATION drug therapy ,CLINICAL trials ,COMBINED modality therapy ,COMPARATIVE studies ,DEBRIDEMENT ,INFECTION ,RESEARCH methodology ,MEDICAL cooperation ,COMPLICATIONS of prosthesis ,RESEARCH ,STAPHYLOCOCCUS ,STAPHYLOCOCCUS aureus ,EVALUATION research ,TREATMENT effectiveness ,RETROSPECTIVE studies ,THERAPEUTICS - Abstract
Background: Staphylococcal species account for more than 50% of periprosthetic joint infections (PJI) and antimicrobial therapy with rifampin-based combination regimens has been shown effective. The present study evaluates the safety and efficacy of clindamycin in combination with rifampin for the management of staphylococcal PJI.Methods: In this retrospective cohort study, patients were included who received clindamycin-rifampin combination therapy to treat a periprosthetic hip or knee infection by Staphylococcus aureus or coagulase-negative staphylococci. Patients were treated according to a standardized treatment algorithm and followed for a median of 54 months. Of the 36 patients with periprosthetic staphylococcal infections, 31 had an infection of the hip, and five had an infection of the knee. Eighteen patients underwent debridement and retention of the implant (DAIR) for an early infection, the other 18 patients underwent revision of loose components in presumed aseptic loosening with unexpected positive cultures.Results: In this study, we report a success rate of 86%, with five recurrent/persistent PJI in 36 treated patients. Cure rate was 78% (14/18) in the DAIR patients and 94% (17/18) in the revision group. Five patients (14%) discontinued clindamycin-rifampin due to side effects. Of the 31 patients completing the clindamycin-rifampin regimen 29 patients (94%) were cured.Conclusion: Combined therapy with clindamycin and rifampin is a safe, well tolerated and effective regimen for the treatment of staphylococcal periprosthetic infection. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
8. Th17 cytokine deficiency in patients with Aspergillus skull base osteomyelitis.
- Author
-
Delsing, Corine E., Becker, Katharina L., Simon, Anna, Kullberg, Bart Jan, Bleeker-Rovers, Chantal P., van de Veerdonk, Frank L., and Netea, Mihai G.
- Subjects
OSTEOMYELITIS ,OTITIS externa ,IMMUNE response ,DISEASE susceptibility ,CANDIDA albicans ,ASPERGILLUS fumigatus ,CYTOKINES ,DISEASE risk factors - Abstract
Background: Fungal skull base osteomyelitis (SBO) is a severe complication of otitis externa or sinonasal infection, and is mainly caused by Aspergillus species. Here we investigate innate and adaptive immune responses in patients with Aspergillus SBO to identify defects in the immune response that could explain the susceptibility to this devastating disease. Methods: Peripheral blood mononuclear cells isolated from six patients with Aspergillus SBO and healthy volunteers were stimulated with various microbial stimuli, among which also the fungal pathogens Candida albicans and Aspergillus fumigatus. The proinflammatory cytokines IL-6, TNFα and IL-1β, and the T-helper cell-derived cytokines IFNγ, IL-17 and IL-22 were measured in cell culture supernatants by ELISA. Results: Proinflammatory cytokine responses did not differ between SBO patients and healthy volunteers. The Candida- and Aspergillus-specific Th17 response (production of IL-17 and IL-22) was significantly decreased in the SBO patients compared to healthy individuals, while Th1 cytokine response (IFNγ production) did not differ between the two groups. Conclusions: We show that patients with Aspergillus skull base osteomyelitis infection have specific defects in Th17 responses. Since IL-17 and IL-22 are important for stimulating antifungal host defense, we hypothesize that strategies that have the ability to improve IL-17 and IL-22 production may be useful as adjuvant immunotherapy in patients with Aspergillus SBO. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. Persistent Lyme Empiric Antibiotic Study Europe (PLEASE) - design of a randomized controlled trial of prolonged antibiotic treatment in patients with persistent symptoms attributed to Lyme borreliosis.
- Author
-
Berende, Anneleen, ter Hofstede, Hadewych J. M., Donders, A. Rogier T., van Middendorp, Henriët, Kessels, Roy P. C., Adang, Eddy M. M., Vos, Fidel J., Evers, Andrea W. M., and Kullberg, Bart Jan
- Subjects
ANTIBIOTICS ,BORRELIA burgdorferi ,LYME disease ,RANDOMIZED controlled trials ,RELAPSING fever ,INFLAMMATORY bowel diseases ,PATIENTS ,THERAPEUTICS - Abstract
Background Lyme borreliosis, a potentially severe tick-borne infection caused by Borrelia burgdorferi, can cause multi-system inflammatory disease. The incidence has been increasing, as has the number of patients with persistent symptoms attributed to Borrelia. These symptoms, also referred to as post-Lyme disease syndrome, may follow an erythema migrans or other Lyme manifestations, and include pain, fatigue, and cognitive disturbances. The optimal duration of treatment for these symptoms is a subject of controversy. The PLEASE study is designed to determine whether prolonged antibiotic treatment leads to better patient outcome than standard treatment. Methods/Design The PLEASE study is a double-blind, randomized, placebo-controlled trial. Based on power analysis and compensating for possible loss to follow-up, a minimum of 255 patients with borreliosis-attributed persistent symptoms are included. These symptoms are either (a) temporally related to an erythema migrans or otherwise proven symptomatic borreliosis, or (b) accompanied by a positive B. burgdorferi IgG or IgM immunoblot. All patients receive open-label ceftriaxone for two weeks. Patients are then randomized (ratio 1:1:1) to blinded oral follow-up treatment for 12 weeks with (I) doxycycline, (II) clarithromycin combined with hydroxychloroquine, or (III) placebo. The primary outcome is the physical component summary score (PCS) of the RAND-36 Health Status Inventory (RAND SF-36) at week 14. Secondary outcomes include physical and mental aspects of health-related quality of life (assessed by the subscales of the RAND SF-36), fatigue, neuropsychological evaluation, physical activity, and cost-effectiveness. Discussion This article describes the background and design issues of the PLEASE study protocol. The results of this study may provide evidence for prescribing or withholding prolonged antibiotic treatment. Trial registration ClinicalTrials.gov: NCT01207739, Netherlands Trial Register: NTR2469 [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
10. The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases
- Author
-
Oever, Jaap ten, Kox, Matthijs, van de Veerdonk, Frank L, Mothapo, Khutso M, Slavcovici, Adriana, Jansen, Tim L, Tweehuysen, Lieke, Giamarellos-Bourboulis, Evangelos J, Schneeberger, Peter M, Wever, Peter C, Stoffels, Monique, Simon, Anna, van der Meer, Jos WM, Johnson, Melissa D, Kullberg, Bart-Jan, Pickkers, Peter, Pachot, Alexandre, Joosten, Leo AB, and Netea, Mihai G
- Abstract
Background: The extracellular domains of cytokine receptor
s are released during inflammation, but little is known about the shedding of Toll-like receptors (TLR) and whether they can be used as diagnostic biomarkers . Methods: The release of sTLR2 and sTLR4 was studied in in-vitro stimulations, as well as in-vivo during experimental human endotoxemia (n = 11, 2 ng/kg LPS), and in plasma of 394 patients with infections (infectious mononucleosis, measles, respiratory tract infections, bacterial sepsis and candidemia) or non-infectious inflammation (Crohn’s disease, gout, rheumatoid arthritis, autoinflammatory syndromes and pancreatitis). Using C-statistics, the value of sTLR2 and sTLR4 levels for discrimination between infections and non-infectious inflammatory diseases, as well as between viral and bacterial infections was analyzed. Results: In-vitro, peripheral blood mononuclear cells released sTLR2 and sTLR4 by exposure to microbial ligands. During experimental human endotoxemia, plasma concentrations peaked after 2 hours (sTLR4) and 4 hours (sTLR2). sTLR4 did not correlate with cytokines, but sTLR2 correlated positively with TNFα (rs = 0.80, P < 0.05), IL-6 (rs = 0.65, P < 0.05), and IL-1Ra (rs = 0.57, P = 0.06), and negatively with IL-10 (rs = -0.58, P = 0.06), respectively. sTLR4 had a similar area under the ROC curve [AUC] for differentiating infectious and non-infectious inflammation compared to CRP: 0.72 (95% CI 0.66-0.79) vers us 0.74 (95% CI 0.69-0.80) [P = 0.80], while sTLR2 had a lower AUC: 0.60 (95% CI 0.54-0.66) [P = 0.0004]. CRP differentiated bacterial infections better from viral infections than sTLR2 and sTLR4: AUC 0.94 (95% CI 0.90-0.96) vers us 0.58 (95% CI 0.51-0.64) and 0.75 (95% CI 0.70-0.80), respectively [P < 0.0001 for both]. Conclusions: sTLrs are released into the circulation, and suggest the possibility to use sTLrs as diagnostic tool in inflammatory conditions. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
11. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series.
- Author
-
Delsing, Corine E., Gresnigt, Mark S., Leentjens, Jenneke, Preijers, Frank, Allantaz Frager, Florence, Kox, Matthijs, Monneret, Guillaume, Venet, Fabienne, Bleeker-Rovers, Chantal P., van de Veerdonk, Frank L., Pickkers, Peter, Pachot, Alexandre, Kullberg, Bart Jan, and Netea, Mihai G.
- Abstract
Background: Invasive fungal infections are very severe infections associated with high mortality rates, despite the availability of new classes of antifungal agents. Based on pathophysiological mechanisms and limited pre-clinical and clinical data, adjunctive immune-stimulatory therapy with interferon-gamma (IFN-γ) may represent a promising candidate to improve outcome of invasive fungal infections by enhancing host defence mechanisms. Methods: In this open-label, prospective case series, we describe eight patients with invasive Candida and/or Aspergillus infections who were treated with recombinant IFN-γ (rIFN-γ, 100 μg s.c., thrice a week) for 2 weeks in addition to standard antifungal therapy. Results: Recombinant IFN-γ treatment in patients with invasive Candida and/or Aspergillus infections partially restored immune function, as characterized by an increased HLA-DR expression in those patients with a baseline expression below 50%, and an enhanced capacity of leukocytes from treated patients to produce proinflammatory cytokines involved in antifungal defence. Conclusions: The present study provides evidence that adjunctive immunotherapy with IFN-γ can restore immune function in fungal sepsis patients, warranting future clinical studies to assess its potential clinical benefit. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
12. Cognitive impairments in patients with persistent symptoms attributed to Lyme disease.
- Author
-
Berende, Anneleen, Agelink van Rentergem, Joost, Evers, Andrea W. M., ter Hofstede, Hadewych J. M., Vos, Fidel J., Kullberg, Bart Jan, and Kessels, Roy P. C.
- Subjects
COGNITIVE testing ,HELPLESSNESS (Psychology) ,PSYCHOLOGICAL factors ,EPISODIC memory ,DISABILITIES ,COGNITIVE neuroscience ,SHORT-term memory - Abstract
Background: Persistent symptoms attributed to Lyme borreliosis often include self-reported cognitive impairment. However, it remains unclear whether these symptoms can be substantiated by objective cognitive testing.Methods: For this observational study, cognitive performance was assessed in 280 adults with persistent symptoms attributed to Lyme borreliosis (as part of baseline data collected for the Dutch PLEASE study). Cognitive testing covered the five major domains: episodic memory, working memory / attention, verbal fluency, information-processing speed and executive function. Patients' profiles of test scores were compared to a large age-, education- and sex-adjusted normative sample using multivariate normative comparison. Performance validity was assessed to detect suboptimal effort, and questionnaires were administered to measure self-reported cognitive complaints, fatigue, anxiety, depressive symptoms and several other psychological factors.Results: Of 280 patients, one was excluded as the test battery could not be completed. Of the remaining 279 patients, 239 (85.4%) displayed sufficient performance validity. Patients with insufficient performance validity felt significantly more helpless and physically fatigued, and less orientated. Furthermore, they had a lower education level and less often paid work. Of the total study cohort 5.7% (n = 16) performed in the impaired range. Among the 239 patients who displayed sufficient performance validity, 2.9% (n = 7) were classified as cognitively impaired. No association between subjective cognitive symptoms and objective impairment was found.Conclusions: Only a small percentage of patients with borreliosis-attributed persistent symptoms have objective cognitive impairment. Performance validity should be taken into account in neuropsychological examinations of these patients. Self-report questionnaires are insufficiently valid to diagnose cognitive impairment.Trial Registration: ClinicalTrials.gov NCT01207739 . Registered 23 September 2010. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
13. Prevalence and determinants of persistent symptoms after treatment for Lyme borreliosis: study protocol for an observational, prospective cohort study (LymeProspect).
- Author
-
Vrijmoeth, Hedwig D., Ursinus, Jeanine, Harms, Margriet G., Zomer, Tizza P., Gauw, Stefanie A., Tulen, Anna D., Kremer, Kristin, Sprong, Hein, Knoop, Hans, Vermeeren, Yolande M., van Kooten, Barend, Joosten, Leo A. B., Kullberg, Bart-Jan, Hovius, Joppe W. R., and van den Wijngaard, Cees C.
- Subjects
LYME disease ,DISEASE prevalence ,SYMPTOMS ,RESEARCH methodology - Abstract
Background: After antibiotic treatment of Lyme borreliosis, a subset of patients report persistent symptoms, also referred to as post-treatment Lyme disease syndrome. The reported prevalence of persistent symptoms varies considerably, and its pathophysiology is under debate. The LymeProspect study has been designed to investigate the prevalence, severity, and a wide range of hypotheses on the etiology of persistent symptoms among patients treated for Lyme borreliosis in the Netherlands.Methods: LymeProspect is a prospective, observational cohort study among adults with proven or probable Lyme borreliosis, either erythema migrans or disseminated manifestations, included at the start of antibiotic treatment. During one year of follow-up, participants are subjected to questionnaires every three months and blood is collected repeatedly during the first three months. The primary outcome is the prevalence of persistent symptoms after treatment, assessed by questionnaires online focusing on fatigue (CIS, subscale fatigue severity), pain (SF-36, subscale pain) and neurocognitive dysfunction (CFQ). Potential microbiological, immunological, genetic, epidemiological and cognitive-behavioral determinants for persistent symptoms are secondary outcome measures. Control cohorts include patients with long-lasting symptoms and unconfirmed Lyme disease, population controls, and subjects having reported a tick bite not followed by Lyme borreliosis.Discussion: This article describes the background and design of the LymeProspect study protocol. This study is characterized by a prospective, explorative and multifaceted design. The results of this study will provide insights into the prevalence and determinants of persistent symptoms after treatment for Lyme borreliosis, and may provide a rationale for preventive and treatment recommendations.Trial Registration: NTR4998 (Netherlands Trial Register). Date of registration: 13 February 2015. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
14. The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases.
- Author
-
Ten Oever J, Kox M, van de Veerdonk FL, Mothapo KM, Slavcovici A, Jansen TL, Tweehuysen L, Giamarellos-Bourboulis EJ, Schneeberger PM, Wever PC, Stoffels M, Simon A, van der Meer JW, Johnson MD, Kullberg BJ, Pickkers P, Pachot A, Joosten LA, and Netea MG
- Subjects
- Adolescent, Adult, Aged, Area Under Curve, C-Reactive Protein metabolism, Case-Control Studies, Child, Child, Preschool, Demography, Female, Humans, Leukocytes, Mononuclear metabolism, Male, Middle Aged, ROC Curve, Solubility, Young Adult, Inflammation blood, Toll-Like Receptor 2 blood, Toll-Like Receptor 4 blood
- Abstract
Background: The extracellular domains of cytokine receptors are released during inflammation, but little is known about the shedding of Toll-like receptors (TLR) and whether they can be used as diagnostic biomarkers., Methods: The release of sTLR2 and sTLR4 was studied in in-vitro stimulations, as well as in-vivo during experimental human endotoxemia (n = 11, 2 ng/kg LPS), and in plasma of 394 patients with infections (infectious mononucleosis, measles, respiratory tract infections, bacterial sepsis and candidemia) or non-infectious inflammation (Crohn's disease, gout, rheumatoid arthritis, autoinflammatory syndromes and pancreatitis). Using C-statistics, the value of sTLR2 and sTLR4 levels for discrimination between infections and non-infectious inflammatory diseases, as well as between viral and bacterial infections was analyzed., Results: In-vitro, peripheral blood mononuclear cells released sTLR2 and sTLR4 by exposure to microbial ligands. During experimental human endotoxemia, plasma concentrations peaked after 2 hours (sTLR4) and 4 hours (sTLR2). sTLR4 did not correlate with cytokines, but sTLR2 correlated positively with TNFα (rs = 0.80, P < 0.05), IL-6 (rs = 0.65, P < 0.05), and IL-1Ra (rs = 0.57, P = 0.06), and negatively with IL-10 (rs = -0.58, P = 0.06), respectively. sTLR4 had a similar area under the ROC curve [AUC] for differentiating infectious and non-infectious inflammation compared to CRP: 0.72 (95% CI 0.66-0.79) versus 0.74 (95% CI 0.69-0.80) [P = 0.80], while sTLR2 had a lower AUC: 0.60 (95% CI 0.54-0.66) [P = 0.0004]. CRP differentiated bacterial infections better from viral infections than sTLR2 and sTLR4: AUC 0.94 (95% CI 0.90-0.96) versus 0.58 (95% CI 0.51-0.64) and 0.75 (95% CI 0.70-0.80), respectively [P < 0.0001 for both]., Conclusions: sTLRs are released into the circulation, and suggest the possibility to use sTLRs as diagnostic tool in inflammatory conditions.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.